
Corporate profile

Company name	Sawai Group Holdings Co., Ltd.
Address	5-2-30, Miyahara, Yodogawa-ku, Osaka 532-0003, Japan
Representative	Mitsuo Sawai, Chairman and President
Business outline	Holding company responsible for the management of the group and its related activities
Paid-in capital	10 billion yen
Founded	April 1, 2021
Fiscal year-end	March 31
Consolidated net sales	201.7 billion yen (FY2025, for the year ended March 31, 2026)
Number of employees	3,630 (FY2025, as of March 31, 2026)
Webpage	https://global.sawaigroup.holdings/



Group companies

Sawai Pharmaceutical Co., Ltd.

Business outline
Manufacturing, sales and import/export of pharmaceuticals and medical devices

Headquarters
5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan

https://global.sawai.co.jp/

Medisa Shinyaku Inc.

Business outline
Manufacturing, sales of pharmaceuticals

Headquarters
5-2-27, Miyahara, Yodogawa-ku, Osaka, Japan

https://www.medisa.co.jp/

Kaken Shoyaku Co., Ltd.

Business outline
Sales of ethical pharmaceuticals and manufacturing of pharmaceutical products

Headquarters
1-11-12, Yamato-cho, Nakano-ku, Tokyo, Japan

https://www.kakenshoyaku.com/

Trust Pharmatech Co., Ltd.

Business outline
Manufacturing of ethical pharmaceuticals

Headquarters
5-15, Yachi, Awara, Fukui, Japan

https://www.trustpharmatech.co.jp/

FrontAct Co., Ltd.

Business outline
Development, manufacturing, sales and marketing, leasing, export and import of products, software, and system including but not limited to medical care, nursing care, welfare, health, and daily living

Headquarters
NMF Kayabacho Bldg. 5F, 1-17-24, Shinkawa, Chuo-ku, Tokyo, Japan

https://frontact-gl.com/

Editorial policy

This report references the International Financial Reporting Standards Foundation's International Integrated Report Framework and includes information that could impact our medium-to long-term corporate value creation and that is connected with information about the Company's strategies, performance, and future projections, as well as non-financial information concerning the environment, society, and governance. The contents herein have been assigned priority internally based on their nature and quantity, risks, opportunities, and dialogues with stakeholders, and have been deemed to be of particular importance.

This report has been prepared by the Group Sustainability Committee, which is supervised by the President, and with the support of the committee's administrative office.

Reporting period:
April 1, 2025 to March 31, 2026 (some information herein falls outside of this period)

Abbreviations used:
In this report, "generic drugs" are abbreviated as either "GE drugs" or "GE."

Reporting scope:
Sawai Group Holdings and its consolidated subsidiaries

A caution concerning forward-looking statements:
This report contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Accordingly, please be aware that the impact of certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report.